Zobrazeno 1 - 10
of 44
pro vyhledávání: '"E J Irvine"'
Autor:
Rishad Khan, Joshua B. Satchwell, E J Irvine, Kirles Bishay, Michael A. Scaffidi, A Nazarian, Reza Gholami, N Griller, Samir C. Grover, D Cohen-Lyons, Jeffrey P. Baker
Background Inflammatory bowel disease (IBD) is associated with a substantial burden on quality of life (QoL). Functional gastrointestinal disorders such as irritable bowel syndrome (IBS) as well as depression and anxiety are more common in patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bf348a7f128691a511aca0ac66bd22c
https://europepmc.org/articles/PMC7043551/
https://europepmc.org/articles/PMC7043551/
Publikováno v:
Alimentary Pharmacology & Therapeutics. 28:1278-1286
Ulcerative colitis (UC) has a major impact on the quality of life (QoL) of affected patients. Patient-reported outcomes have not been thoroughly evaluated in patients with UC receiving oral mesalazine (mesalamine).To examine the effect of mesalazine
Publikováno v:
Inflammatory Bowel Diseases. 13:903-910
Background/Aims Inflammatory bowel disease affects the quality of a patient’s life in many ways, but no validated instrument for measuring disease-specific quality of life in these patients is available for use in Mainland China. The aim of our stu
Autor:
E J Irvine, John Marshall
Publikováno v:
Alimentary Pharmacology & Therapeutics. 9:293-300
SUMMARY Background: To summarize and quantify the evidence supporting rectal 5- or 4-aminosalicylate (ASA) therapies for disease exacerbation or remission maintenance in distal ulcerative colitis, we performed a meta-analysis. Methods: All randomized
Autor:
E. J. Irvine
Publikováno v:
Alimentary Pharmacology & Therapeutics. 20:54-59
The management of chronic illness is becoming increasingly patient-centred. Although patients with inflammatory bowel disease have a normal life expectancy, most individuals experience an impact of inflammatory bowel disease on their daily lives as w
Autor:
E J Irvine
Publikováno v:
Gut. 53:iv35-iv39
Health related quality of life (HRQoL) is determined by both disease and non-disease related factors. Several studies have reported significant HRQoL impairment in GORD patients compared with the general population. Disease severity correlates strong
Autor:
Ebbe Langholz, S. Orm, M. R. Lassen, D. Lowson, Colm O'Morain, E. J. Irvine, S. Kiilerich, K. Leiper, Alastair Forbes, Stuart Bloom
Publikováno v:
Alimentary Pharmacology & Therapeutics. 19:871-878
Heparin has anti-inflammatory and immunomodulatory activity which may be of therapeutic benefit in the treatment of ulcerative colitis.
Publikováno v:
American Journal of Gastroenterology. 99:319-326
To assess the prevalence and determinants of alternative medicine (AM) use in gastroenterology outpatients and those with inflammatory bowel disease (IBD).An 80-item questionnaire, addressing symptoms, general health, quality of life, and AM use, was
Publikováno v:
Digestive Diseases and Sciences. 47:225-235
The Rome II criteria and questionnaires developed to identify functional gastrointestinal disorders have not been evaluated. Our objectives were to determine the prevalence of functional gastrointestinal disorders in Canada, compare our results with
Publikováno v:
The American Journal of Gastroenterology. 96:3130-3137
The prevalence of functional constipation is highly variable among epidemiological surveys and may relate to the definitions applied. We estimated the population prevalence of self-reported, Rome I-defined, and Rome II-defined constipation in Canada